We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Rubius Therapeutics Inc | NASDAQ:RUBY | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.083 | 0.0888 | 0.0894 | 0 | 01:00:00 |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 11 | | | |
| | | | 24 | | | |
| | | | 25 | | | |
| | | | 28 | | | |
| | | | 28 | | | |
| | | | 29 | | | |
| | | | 30 | | | |
| | | | A-1 | | | |
| | | | B-1 | | |
| | |
Shares beneficially owned
|
| |||||||||
Name and address of beneficial owner
|
| |
Number
|
| |
Percentage
|
| ||||||
5% Stockholders: | | | | | | | | | | | | | |
Entities affiliated with the Flagship Pioneering Funds(1)
|
| | | | 38,506,526 | | | | | | 42.6% | | |
FMR LLC(2)
|
| | | | 12,376,153 | | | | | | 13.7% | | |
David R. Epstein(3)
|
| | | | 4,900,012 | | | | | | 5.4% | | |
Baillie Gifford & Co(4)
|
| | | | 4,869,126 | | | | | | 5.4% | | |
Named Executive Officers and Directors: | | | | | | | | | | | | | |
Pablo J. Cagnoni, M.D.(5)
|
| | |
|
4,617,478
|
| | | |
|
4.9%
|
| |
Jose Carmona(6)
|
| | |
|
—
|
| | | |
|
—
|
| |
Dannielle Appelhans(7)
|
| | |
|
97,885
|
| | | |
|
*
|
| |
Maiken Keson-Brookes(8)
|
| | |
|
5,343
|
| | | |
|
*
|
| |
Laurence Turka, M.D.(9)
|
| | | | 382,452 | | | | | | * | | |
Catherine A. Sohn, Pharm.D.(10)
|
| | | | 232,500 | | | | | | * | | |
Sir Jonathan R. Symonds, CBE(11)
|
| | | | 295,000 | | | | | | * | | |
All executive officers and directors as a group (7 persons)(12)
|
| | | | 5,630,658 | | | | | | 5.9% | | |
1 Year Rubius Therapeutics Chart |
1 Month Rubius Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions